Wheaton Acquires Bioreactor Flask Line from Wilson Wolf
|
By LabMedica International staff writers Posted on 25 Jul 2012 |
Wheaton Industries (Millville, NJ, USA) has acquired the CELLine bioreactor flask line for antibody and protein production from Wilson Wolf Manufacturing Corp. (New Brighton, MN, USA).
Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.
CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.
“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Related Links:
Wheaton Industries
Wilson Wolf Manufacturing
Wheaton has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corp. Wheaton has also entered into a long term strategic partnership with Wilson Wolf Manufacturing for additional product development in high density cell culture devices for the production of concentrated, cell secreted products.
CELLine flasks are easy to implement and are known worldwide for small-scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small-scale bioproduction for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be labor-intensive, result in low cell density, and require significant purification. The CELLine flasks address these three areas of limitation in a single use, repeatable technology. CELLine flasks are ready-to-use and disposable, and generate high cell density and high product concentration, while considerably reducing culture and processing time.
“We are excited to bring this innovative, high growth technology to Wheaton and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing Wheaton portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, president of Wheaton. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Related Links:
Wheaton Industries
Wilson Wolf Manufacturing
Latest BioResearch News
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
- Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
- Population-Scale Proteomics Study Identifies New Genetic-Protein Links
- Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
- Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
- New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
- New Immune Target Could Support More Precise High Blood Pressure Treatment
- New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
- Researchers Identify Shared Molecular Networks Behind Fatigue-Related Illnesses
- Blood Metabolite Signature Predicts ALS Progression and Points to Treatment Strategy
- Whole-Blood Extracellular Vesicle Analysis Captures Molecular Signals Missed by Plasma Testing
- Age-Related Genomic Differences Could Refine Treatment Decisions in Lung Cancer
- Computational Tool Identifies Central Asthma Genes for Target Discovery
Channels
Clinical Chemistry
view channel
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more
GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read moreIndustry
view channel
Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more







